Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".
about
Animal models of heart failure with preserved ejection fractionZinc and the prooxidant heart failure phenotypeAnti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockadeThe emperor's new clothes: PDE5 and the heartQuantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling.Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction.Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes.Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptorRole of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction.Targeting the aldosterone pathway in cardiovascular disease.Aldosterone receptor antagonists: current perspectives and therapiesAldosterone and the heart: still an unresolved issue?Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fractionTargeting osteopontin, the silent partner of Na+/H+ exchanger isoform 1 in cardiac remodeling.Treatment of Primary Aldosteronism and Organ Protection.Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction.Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction.Influence of periostin-positive cell-specific Klf5 deletion on aortic thickening in DOCA-salt hypertensive mice.Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening.Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives.Diastolic dysfunction and contrast-induced nephropathy in patients undergoing coronary angiography.Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis.
P2860
Q26764971-BF4F6C23-B913-4BEA-B752-54C7E61E19C6Q26824041-89BA3A93-6A2A-4F6C-BC57-7FE1883B5CDFQ28535743-31A910C3-7D32-4C6F-94E0-CFDB251DDFF5Q28543897-719D7683-937B-44B7-AC15-87BCA1905B38Q30659130-6A775480-DFD5-4B99-8FC1-23017EFC0C45Q34559877-CD602E3E-206B-4E80-86FE-8E6B33A63653Q34784461-7E55A1A0-CFCD-418F-A094-3F48908627B6Q34873021-EA4DD072-EFC7-49CC-972D-F83B4206C85DQ35071304-60A137EA-0096-4416-BBF9-8B1CA822748EQ35581462-83A9AF1A-2A78-42AD-B806-960912F94806Q36935635-043DE8C5-A000-4B63-8E71-C892FD9E2EFCQ37292468-BF39163C-2ABD-4345-AF82-89FE8F42DF86Q37951665-16724E63-A934-4AE5-AE68-798D82E33D82Q38120241-D4FBA0C0-0349-4026-866E-7373937BF084Q38263511-C441AE15-3690-456F-9966-554B0C555EA5Q38285243-D4ABE680-0A35-488C-ACAB-09F0535E53F3Q38354012-BC1D69D6-8653-4C98-A336-C9FC16F5BD25Q38527834-F323758E-7A6D-4D3E-B71F-F0C4DB1FCB73Q39272526-8EEA881C-D9A9-4F97-8199-8E024A63C019Q42382004-D5948CAE-3D02-489B-9FD4-527E88EC11A7Q42765706-0B7D47C1-390E-4AB9-97B0-DADBF1C840B6Q43424401-02729223-4C2C-4E88-B74D-B8511081CD04Q49203906-3F5629C1-3630-43F9-B515-CA091EEBF73FQ50143463-2FF6C3A2-219E-470A-847E-B8D11F886197Q51006628-FEF1AA02-F103-4387-9F0F-B1A87ED6EC3AQ53113411-7106C735-7BA4-4994-B3FE-462D3A97EF92
P2860
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@ast
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@en
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@nl
type
label
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@ast
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@en
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@nl
prefLabel
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@ast
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@en
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@nl
P2093
P2860
P1433
P1476
Mineralocorticoid accelerates ...... tion via "nongenomic effects".
@en
P2093
Carolyn S P Lam
John C Burnett
Josef Korinek
Katarina Larsen
Margaret M Redfield
Robert D Simari
Selma F Mohammed
Tomohito Ohtani
P2860
P304
P356
10.1161/CIRCULATIONAHA.109.915215
P407
P577
2010-07-12T00:00:00Z